News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results , with sales up 10.3% year on year to $3.79 billion. Its ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stock has experienced a notable downturn, touching a 52-week low of $666. With a ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

REGENERON PHARMACEUTICALS ($REGN) posted quarterly earnings results on Tuesday, February 4th. The company reported earnings of $12.07 per share, beating estimates of ...

While Regeneron has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question ...

Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a market perform rating to an ...

REGENERON PHARMACEUTICALS ($REGN) is expected to release its quarterly earnings data on Tuesday, February 4th before market open. Analysts are expecting revenue of ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $71.75 billion, has been navigating a complex landscape of opportunities and challenges in recent months. According to ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by equities research analysts at Leerink Partners from $980.00 to $862.00 in a research note issued on Tuesday.

Kingsview Wealth Management LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 16.5% in the fourth quarter, according to the company in its most recent ...